Peter F. J. Schulte
Research Subjects
Peter F. J. Schulte has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Hélène Verdoux
Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, team Pharmacoepidemiology, UMR 1219, F-33000 Bordeaux, France
9 shared publications - Dan Cohen
Dutch Clozapine Collaboration Group, Castricum, The Netherlands
7 shared publications - Carlos De Las Cuevas
University of La Laguna
6 shared publications - Christopher Rohde
Department of Clinical Medicine, Aarhus University
6 shared publications - Espen Molden
Center for Psychopharmacology Diakonhjemmet Hospital Oslo Norway
6 shared publications - Georgios Schoretsanitis
Department of Psychiatry, Lausanne University Hospital and University of Lausanne, CH-1008 Prilly Lausanne, Switzerland; Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neurosciences, Lausanne University Hospital and University of Lausanne, CH-1005 Lausanne, Switzerland; The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY 11004, USA; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY 11549, USA
6 shared publications
Latest Publications
- Open Access
- 12 February 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 153 (6) , 595-609
Involuntary Clozapine Treatment: A Systematic Review
Introduction: We aimed to synthesize the information relevant for clinical practice on involuntary clozapine treatment. Methods: Articles were identified with MEDLINE, Web of Sciences and PsycINFO search from inception through September 2025 (PROSPERO database registration CRD420251234475). We included all articles addressing issues related to involuntary clozapine treatment irrespective of the route of administration, i.e., oral, intra‐muscular (IM) or nasogastric. Data were synthesized narratively. Results: Of the 29 identified articles, most clinical studies ( n = 18) on people prescribed involuntary clozapine treatment ( n = 236) were case reports/series or chart reviews. IM or nasogastric routes were the last‐resort treatment for people with extremely severe psychotic disorders presenting with risky behavior. The decisional process was often lengthy due to the complex legal and ethical issues raised by involuntary treatment and restricted access to the unlicensed IM formulation. In nearly half of cases, the oral route was accepted after the decision to perform IM or nasogastric administration. Pain at the injection site was the most frequent adverse event after IM administration. Transition to this route occurred rapidly in the vast majority of the other cases, most often allowing a dramatic reduction in the severity of target symptoms and coercive measures. Clozapine was maintained orally after the acute phase in the majority of people with involuntary administration. Conclusions: Although the body of evidence supporting the use of involuntary clozapine treatment is mostly drawn from small observational studies, their findings suggest that this last‐resort option may save the life and promote recovery of people for whom other treatments have failed. Access to IM clozapine is currently restricted in most countries. Whether this barrier to clozapine treatment for severely ill people with impaired decision‐making capacities should be overcome in other countries needs to be further addressed. Registration: PROSPERO database registration CRD420251234475.
- 12 February 2026
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 153 (6) , 595-609
Open AccessInvoluntary Clozapine Treatment: A Systematic Review
Introduction: We aimed to synthesize the information relevant for clinical practice on involuntary clozapine treatment. Methods: Articles were identified with MEDLINE, Web of Sciences and PsycINFO search from inception through September 2025 (PROSPERO database registration CRD420251234475). We included all articles addressing issues related to involuntary clozapine treatment irrespective of the route of administration, i.e., oral, intra‐muscular (IM) or nasogastric. Data were synthesized narratively. Results: Of the 29 identified articles, most clinical studies ( n = 18) on people prescribed involuntary clozapine treatment ( n = 236) were case reports/series or chart reviews. IM or nasogastric routes were the last‐resort treatment for people with extremely severe psychotic disorders presenting with risky behavior. The decisional process was often lengthy due to the complex legal and ethical issues raised by involuntary treatment and restricted access to the unlicensed IM formulation. In nearly half of cases, the oral route was accepted after the decision to perform IM or nasogastric administration. Pain at the injection site was the most frequent adverse event after IM administration. Transition to this route occurred rapidly in the vast majority of the other cases, most often allowing a dramatic reduction in the severity of target symptoms and coercive measures. Clozapine was maintained orally after the acute phase in the majority of people with involuntary administration. Conclusions: Although the body of evidence supporting the use of involuntary clozapine treatment is mostly drawn from small observational studies, their findings suggest that this last‐resort option may save the life and promote recovery of people for whom other treatments have failed. Access to IM clozapine is currently restricted in most countries. Whether this barrier to clozapine treatment for severely ill people with impaired decision‐making capacities should be overcome in other countries needs to be further addressed. Registration: PROSPERO database registration CRD420251234475.
- 28 September 2025
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 152 (6) , 473-475
Barriers to Clozapine Use in Europe: A New Hope
- 28 September 2025
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 152 (6) , 473-475
Barriers to Clozapine Use in Europe: A New Hope
- Open Access
- 24 July 2025
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 27 (1) , 249-264
Light therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force
The International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force conducted a comprehensive review to deliver concise evidence-based recommendations on the use of bright light therapy (BLT) for bipolar disorder (BD). Adjunctive BLT is likely an efficacious acute treatment for bipolar depression as implicated by higher quality evidence. The position of maintenance BLT for relapse prevention awaits further investigation. Protocols of effective BLT in BD are similar to parameters indicated for treatment of seasonal and non-seasonal major depressive disorder. Anti-manic prophylaxis (especially for BD-I) and clinical monitoring are recommended with initiation of and ongoing light treatment. Administer BLT daily, preferably in the morning or at mid-day. If mornings are prohibitive, then mid-day exposure, implemented to avoid excessively early wake times, is an acceptable alternative. Informed by the literature, target 30 min/day of BLT exposure. Patients wary of emergent hypomania or partial responders, can initiate 15 min/day and increase by 15 min each week to full response (or 30-60 min/day by the fourth week). Consider patient centred outcome assessments to evaluate mood response, safety and side effects. Clinical improvement is typically observed within 1-2 weeks, with response/remission expected by 4-6 weeks. Integration of BLT with other chronotherapeutic strategies may enhance long-term efficacy.
- 24 July 2025
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 27 (1) , 249-264
Open AccessLight therapy for bipolar disorders: Clinical recommendations from the international society for bipolar disorders (ISBD) Chronobiology and Chronotherapy Task Force
The International Society for Bipolar Disorders (ISBD) Chronobiology and Chronotherapy Task Force conducted a comprehensive review to deliver concise evidence-based recommendations on the use of bright light therapy (BLT) for bipolar disorder (BD). Adjunctive BLT is likely an efficacious acute treatment for bipolar depression as implicated by higher quality evidence. The position of maintenance BLT for relapse prevention awaits further investigation. Protocols of effective BLT in BD are similar to parameters indicated for treatment of seasonal and non-seasonal major depressive disorder. Anti-manic prophylaxis (especially for BD-I) and clinical monitoring are recommended with initiation of and ongoing light treatment. Administer BLT daily, preferably in the morning or at mid-day. If mornings are prohibitive, then mid-day exposure, implemented to avoid excessively early wake times, is an acceptable alternative. Informed by the literature, target 30 min/day of BLT exposure. Patients wary of emergent hypomania or partial responders, can initiate 15 min/day and increase by 15 min each week to full response (or 30-60 min/day by the fourth week). Consider patient centred outcome assessments to evaluate mood response, safety and side effects. Clinical improvement is typically observed within 1-2 weeks, with response/remission expected by 4-6 weeks. Integration of BLT with other chronotherapeutic strategies may enhance long-term efficacy.
- Top Cited PapersOpen Access
- 10 January 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-13
The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
- 10 January 2025
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 68 (1) , 1-13
Top Cited PapersOpen AccessThe time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force
- 22 March 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 267, 72-74
Recovery from leukopenia after discontinuation of clozapine does not exclude lymphoma
- 22 March 2024
- Published by Elsevier in Schizophrenia Research
- Vol. 267, 72-74
Recovery from leukopenia after discontinuation of clozapine does not exclude lymphoma
- Open Access
- 7 December 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 175-188
Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
- 7 December 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 175-188
Open AccessRevealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
- 26 September 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 74-81
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?
- 26 September 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 74-81
Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?
- 22 July 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 293-301
Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
- 22 July 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 293-301
Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients
- 20 July 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 285-288
Can clozapine be used for treatment-refractory behavioral and psychological symptoms in dementia patients?
- 20 July 2023
- Published by Elsevier in Schizophrenia Research
- Vol. 268, 285-288
Can clozapine be used for treatment-refractory behavioral and psychological symptoms in dementia patients?